Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib in hospitalized COVID-19 patients
NCT04629703Phase 3Completed
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Mar 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Fostamatinib + SOC with Placebo + SOC (2 arms). Primary endpoint: Number of days on oxygen. Started Mar 2021; status: completed.
02
Drugs
fostamatinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04629703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629703.